The Vision Council (TVC) has published a 2-part research report, “Focused inSights 2025: Myopia Management,” which examines global pediatric myopia treatment strategies alongside a survey of US eyecare providers. The report reviews treatment adoption, regulatory approvals, and prescribing practices across multiple regions, while also analyzing how US clinicians approach diagnosis, management, and patient education.

The first section, “Comparative Myopia Treatment Strategies,” compares regulatory environments and product availability in the United States, Canada, the United Kingdom, and the European Union. It covers 4 treatment categories: low-dose atropine drops, myopia control spectacle lenses, multifocal or dual-focus daily soft contact lenses, and orthokeratology. Key developments highlighted by TVC include the European Union’s approval of Ryjunea atropine drops and France’s reimbursement of myopia control spectacle lenses.

The second section, “Provider Approaches to Myopia Management Survey,” is based on responses from 293 optometrists, practice owners, and managers. Findings highlight how US practices are implementing myopia management:

• Annual screenings are recommended by 91% of providers.

• Roughly 70% of practices report offering myopia management for children.

• The main motivations for treatment include slowing the progression of myopia (78%), reducing complication risks (78%), and improving long-term eye health (71%).

• Excessive screen time and genetics are each identified as leading risk factors by 82% of providers, while limited outdoor activity is cited by 77%.

• Cost remains the most significant barrier (86%), followed by parental understanding (56%) and patient compliance (49%).

The full report is available here as a complimentary download for members and for nonmembers to purchase.